Is there still a room for crizotinib in first-line setting in ALK-positive NSCLC patients?

Previous Page

Next Page

Page Background

3

rd

G ALK and resistance profile

Yoda – Clin Cancer Res 2018

Lorlatinib, 35% co-mutations.

G1202R + L1196M

impairs lorlatinib efficacy